At end point , compared to placebo , desvenlafaxine was associated with a significantly greater decrease in HDRS17 total scores ( last-observation-carried-forward analysis ; adjusted mean change from baseline -9.9 vs -8.1 , respectively ; P = .004 ) and significant improvements on the CGI-I ( P < .001 ) , MADRS ( P = .002 ) , SDS ( P = .038 ) , and VAS-PI ( P < .001 ) .